Esteban A Orellana
Overview
Explore the profile of Esteban A Orellana including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
666
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bowles I, Orellana E
J Mol Biol
. 2025 Mar;
:169046.
PMID: 40057447
The vast array of cellular ribonucleic acid (RNA) modifications hold a crucial role in regulating RNA stability, folding, localization, and the accuracy of translation. Numerous diseases have been associated with...
2.
Ali R, Orellana E, Lee S, Chae Y, Chen Y, Clauwaert J, et al.
Mol Cell
. 2025 Feb;
85(5):948-961.e11.
PMID: 39892392
Amplification of chromosomal material derived from 12q13-15 is common in human cancer and believed to result in overexpression of multiple collaborating oncogenes. To define the oncogenes involved, we overexpressed genes...
3.
Abdelaal A, Sohal I, Iyer S, Sudarshan K, Orellana E, Ozcan K, et al.
Mol Ther Nucleic Acids
. 2024 May;
35(2):102193.
PMID: 38745855
Use of tumor-suppressive microRNAs (miRNAs) as anti-cancer agents is hindered by the lack of effective delivery vehicles, entrapment of the miRNA within endocytic compartments, and rapid degradation of miRNA by...
4.
Li J, Wang L, Hahn Q, Nowak R, Viennet T, Orellana E, et al.
Nature
. 2023 Jan;
613(7943):391-397.
PMID: 36599985
Chemical modifications of RNA have key roles in many biological processes. N-methylguanosine (mG) is required for integrity and stability of a large subset of tRNAs. The methyltransferase 1-WD repeat-containing protein...
5.
Orellana E, Siegal E, Gregory R
Nat Rev Genet
. 2022 Jun;
23(11):651-664.
PMID: 35681060
tRNAs are key adaptor molecules that decipher the genetic code during translation of mRNAs in protein synthesis. In contrast to the traditional view of tRNAs as ubiquitously expressed housekeeping molecules,...
6.
Orellana E, Liu Q, Yankova E, Pirouz M, De Braekeleer E, Zhang W, et al.
Mol Cell
. 2021 Aug;
81(16):3323-3338.e14.
PMID: 34352207
The emerging "epitranscriptomics" field is providing insights into the biological and pathological roles of different RNA modifications. The RNA methyltransferase METTL1 catalyzes N7-methylguanosine (mG) modification of tRNAs. Here we find...
7.
Chen H, Gu L, Orellana E, Wang Y, Guo J, Liu Q, et al.
Cell Res
. 2020 Jan;
30(6):544-547.
PMID: 31913360
No abstract available.
8.
Orellana E, Li C, Lisevick A, Kasinski A
Cell Cycle
. 2019 Jul;
18(15):1798-1811.
PMID: 31258013
Efforts to search for better treatment options for cancer have been a priority, and due to these efforts, new alternative therapies have emerged. For instance, clinically relevant tumor-suppressive microRNAs that...
9.
Orellana E, Abdelaal A, Rangasamy L, Tenneti S, Myoung S, Low P, et al.
Mol Ther Nucleic Acids
. 2019 May;
16:505-518.
PMID: 31071527
The therapeutic promise of small-RNA therapeutics is limited, not only by the lack of delivery vehicles, but also by the inability of the small RNAs to reach intracellular compartments where...
10.
Rangasamy L, Chelvam V, Kanduluru A, Srinivasarao M, Bandara N, You F, et al.
Bioconjug Chem
. 2018 Feb;
29(4):1047-1059.
PMID: 29446616
Although peptides, antibodies/antibody fragments, siRNAs, antisense DNAs, enzymes, and aptamers are all under development as possible therapeutic agents, the breadth of their applications has been severely compromised by their inability...